Evidence map›Paper›PMID 38713312›Full record

ArticleCerebellum (London, England)2024

Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia.

Michele Potashman, Katja Rudell, Ivanna Pavisic, Naomi Suminski, Rinchen Doma, Maggie Heinrich, Linda Abetz-Webb, Melissa Wolfe Beiner, Sheng-Han Kuo, Liana S Rosenthal and 8 more

Abstract read
In one paragraph

Article in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michele PotashmanBiohaven Pharmaceuticals, Inc, New Haven, CT, USA. michele.potashman@biohavenpharma.com.
Katja RudellCOA Science, Parexel International, London, UK.
Ivanna PavisicCOA Science, Parexel International, London, UK.
Naomi SuminskiCOA Science, Parexel International, London, UK.
Rinchen DomaCOA Science, Parexel International, London, UK.
Maggie HeinrichCOA Science, Parexel International, London, UK.
Linda Abetz-WebbPatient-Centered Outcomes Assessments, Macclesfield, UK.
Melissa Wolfe BeinerBiohaven Pharmaceuticals, Inc, New Haven, CT, USA.
Sheng-Han KuoDepartment of Neurology, Columbia University, New York, NY, USA.
Liana S RosenthalDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Theresa ZesiwiczDepartment of Neurology, Ataxia Research Center, University of South Florida, Tampa, FL, USA.
Terry D FifeDepartment of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix, AZ, USA.
Bart P van de WarrenburgDepartment of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Giovanni RistoriDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Matthis SynofzikDivision of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Susan PerlmanDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jeremy D SchmahmannAtaxia Center, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Gilbert L'ItalienBiohaven Pharmaceuticals, Inc, New Haven, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The functional Scale for the Assessment and Rating of Ataxia (f-SARA) assesses Gait, Stance, Sitting, and Speech. It was developed as a potentially clinically meaningful measure of spinocerebellar ataxia (SCA) progression for clinical trial use. Here, we evaluated content validity of the f-SARA. Qualitative interviews were conducted among individuals with SCA1 (n = 1) and SCA3 (n = 6) and healthcare professionals (HCPs) with SCA expertise (USA, n = 5; Europe, n = 3). Interviews evaluated symptoms and signs of SCA and relevance of f-SARA concepts for SCA. HCP cognitive debriefing was conducted. Interviews were recorded, transcribed, coded, and analyzed by ATLAS.TI software. Individuals with SCA1 and 3 reported 85 symptoms, signs, and impacts of SCA. All indicated difficulties with walking, stance, balance, speech, fatigue, emotions, and work. All individuals with SCA1 and 3 considered Gait, Stance, and Speech relevant f-SARA concepts; 3 considered Sitting relevant (42.9%). All HCPs considered Gait and Speech relevant; 5 (62.5%) indicated Stance was relevant. Sitting was considered a late-stage disease indicator. Most HCPs suggested inclusion of appendicular items would enhance clinical relevance. Cognitive debriefing supported clarity and comprehension of f-SARA. Maintaining current abilities on f-SARA items for 1 year was considered meaningful for most individuals with SCA1 and 3. All HCPs considered meaningful changes as stability in f-SARA score over 1-2 years, 1-2-point change in total f-SARA score, and deviation from natural history. These results support content validity of f-SARA for assessing SCA disease progression in clinical trials.

Indexed as

Spinocerebellar AtaxiasAdultAgedDisease ProgressionFemaleGaitHumansMaleMiddle AgedReproducibility of ResultsSeverity of Illness IndexClinical outcome assessmentCognitive debriefingConcept elicitationf-SARASpinocerebellar ataxia

Identifiers

PMID38713312
PMCPMC11489265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.